Cell aggregation increases drug resistance of acute myeloid leukemia cells

被引:0
|
作者
Fadeev R.S. [1 ]
Solovieva M.E. [1 ]
Slyadovskiy D.A. [3 ]
Zakharov S.G. [4 ]
Fadeeva I.S. [1 ,2 ]
Senotov A.S. [5 ]
Dolgikh N.V. [1 ,2 ]
Golenkov A.K. [4 ]
Akatov V.S. [1 ,2 ]
机构
[1] Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Moscow oblast
[2] Pushchino State Natural Science Institute, Pushchino, Moscow oblast
[3] Nizhni Novgorod Lobachevsky National Research University, Nizhni Novgorod
[4] Vladimirsky Moscow Regional Research Clinical Institute (MONIKI), Moscow
[5] Saratov Medical Center of the FMBA of Russia, Balakovo, Saratov oblast
基金
俄罗斯基础研究基金会;
关键词
acute myeloid leukemia; drug resistance; intercellular adhesion; multicellular aggregates;
D O I
10.1134/S1990747815020063
中图分类号
学科分类号
摘要
One of the major causes of low efficiency of the therapy for acute myeloid leukemia is drug resistance of leukemic cells. Microenvironment plays a key role in formation of the phenotype of leukemic cell drug resistance. Investigation of the mechanisms of microenvironment-mediated drug resistance is important to identify novel pharmacological targets for the acute myeloid leukemia therapy. We studied the role of cell aggregation in the drug resistance of leukemic cells. We showed the increased resistance of acute myeloid leukemia cells THP-1 to bortezomib, doxorubicin and fludarabine in multicellular aggregates. In the multicellular aggregates of THP-1 with the higher drug resistance, cell proliferation activity did not change, while the intracellular level of anti-apoptotic protein Bcl-2 increased. Inhibition of the aggregation of THP-1 cells prevented drug resistance. This work demonstrates the involvement of cell aggregation in the formation of drug resistance phenotype in leukemic cells. © 2015, Pleiades Publishing, Ltd.
引用
收藏
页码:135 / 143
页数:8
相关论文
共 50 条
  • [41] Venetoclax Resistance in Acute Myeloid Leukemia
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Collette, Yves
    Vey, Norbert
    CANCERS, 2024, 16 (06)
  • [42] Study of stem cell niche favoring drug resistance, immune suppression and maintenance of leukemia supportive microenvironment in acute myeloid leukemia
    Kode, J.
    Nagare, M.
    Khattry, N.
    Sengar, M.
    Punatar, S.
    Gokarn, A.
    Chiplunkar, S.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1785 - 1786
  • [43] Acute Myeloid Leukemia Stem Cells Cells Are Rare and Heterogeneous in Human Acute Myeloid Leukemia
    Sarry, Jean-Emmanuel
    Murphy, Kathleen
    Danet-Desnoyers, Gwenn-Ael
    Carroll, Martin
    BLOOD, 2009, 114 (22) : 162 - 163
  • [44] Loss of KDM6A confers drug resistance in acute myeloid leukemia
    Stief, Sophie M.
    Hanneforth, Anna-Li
    Weser, Sabrina
    Mattes, Raphael
    Carlet, Michela
    Liu, Wen-Hsin
    Bartoschek, Michael D.
    Moreno, Helena Dominguez
    Oettle, Matthias
    Kempf, Julia
    Vick, Binje
    Ksienzyk, Bianka
    Tizazu, Belay
    Rothenberg-Thurley, Maja
    Quentmeier, Hilmar
    Hiddemann, Wolfgang
    Vosberg, Sebastian
    Greif, Philipp A.
    Metzeler, Klaus H.
    Schotta, Gunnar
    Bultmann, Sebastian
    Jeremias, Irmela
    Leonhardt, Heinrich
    Spiekermann, Karsten
    LEUKEMIA, 2020, 34 (01) : 50 - 62
  • [45] Drug resistance testing of acute myeloid leukemia in adults using the MTT assay
    Stute, N
    Köhler, T
    Lehmann, L
    Wetzstein, W
    Ehninger, G
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III, 1999, 457 : 445 - 452
  • [46] Loss of KDM6A Confers Drug Resistance in Acute Myeloid Leukemia
    Stief, Sophie M.
    Hanneforth, Anna-Li
    Mattes, Raphael
    Weser, Sabrina
    Vick, Binje
    Bartoschek, Michael D.
    Moreno, Helena Dominguez
    Liu, Wen-Hsin
    Ksienzyk, Bianka
    Rothenberg-Thurley, Maja
    Quentmeier, Hilmar
    Hiddemann, Wolfgang
    Metzeler, Klaus H.
    Schotta, Gunnar
    Bultmann, Sebastian
    Jeremias, Irmela
    Leonhardt, Heinrich
    Spiekermann, Karsten
    BLOOD, 2018, 132
  • [47] Suppressing Hedgehog signaling reverses drug resistance of refractory acute myeloid leukemia
    Huang, Kaikai
    Sun, Zhiqiang
    Ding, Bingjie
    Jiang, Xuejie
    Wang, Zhixiang
    Zhu, Yufeng
    Meng, Fanyi
    ONCOTARGETS AND THERAPY, 2019, 12 : 7477 - 7488
  • [48] The use of the MTT assay to study drug resistance in acute myeloid leukemia: An update
    Sargent, J
    Elgie, A
    Williamson, C
    Bowen, S
    Taylor, C
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II, 1997, 3 : 33 - 41
  • [49] Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?
    Ganesan, Saravanan
    Mathews, Vikram
    Vyas, Neha
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (09) : 1401 - 1411
  • [50] Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities
    Zwaan, CM
    Kaspers, GJL
    Pieters, R
    Hählen, K
    Huismans, DR
    Zimmermann, M
    Harbott, J
    Slater, RM
    Creutzig, U
    Veerman, AJP
    BLOOD, 2002, 100 (09) : 3352 - 3360